Publications
Hofer L.M, Kweyamba P.A, Sayi R.M, Chabo M.S, Mwanga R, Maitra S.L, Somboka M.M, Schnoz A, Golumbeanu M, Schneeberger P.H.H, Ross A, Habtewold T, Nsanzabana C, Moore S.J, Tambwe M.M. Additional blood meals increase sporozoite infection in Anopheles mosquitoes but not Plasmodium falciparum genetic diversity. Sci Rep. 2024;14:17467. DOI: 10.1038/s41598-024-67990-y
Hosch S, Wagner P, Giger J.N, Dubach N, Saavedra E, Perno C.F, Gody J.C, Pagonendji M.S, Ngoagouni C, Ndoua C, Nsanzabana C, Vickos U, Daubenberger C, Schindler T. PHARE: a bioinformatics pipeline for compositional profiling of multiclonal Plasmodium falciparum infections from long-read Nanopore sequencing data. J Antimicrob Chemother. 2024;79(5):987-996. DOI: 10.1093/jac/dkae060
Schnoz A, Beuret C, Concu M, Hosch S, Rutaihwa L.K, Golumbeanu M, Nsanzabana C. Genotyping methods to distinguish Plasmodium falciparum recrudescence from new infection for the assessment of antimalarial drug efficacy: an observational, single-centre, comparison study. Lancet Microbe. 2024(in press). DOI: 10.1016/s2666-5247(24)00153-8
Bechtold P, Wagner P, Hosch S, Gregorini M, Stark W.J, Gody J.C, Kodia-Lenguetama E.R, Pagonendji M.S, Donfack O.T, Phiri W.P, García G.A, Nsanzabana C, Daubenberger C.A, Schindler T, Vickos U. Development and evaluation of PlasmoPod: a cartridge-based nucleic acid amplification test for rapid malaria diagnosis and surveillance. PLOS Glob Public Health. 2023;3(9):e0001516. DOI: 10.1371/journal.pgph.0001516
Golumbeanu M, Edi C.A.V, Hetzel M.W, Koepfli C, Nsanzabana C. Bridging the gap from molecular surveillance to programmatic decisions for malaria control and elimination. Am J Trop Med Hyg. 2023(in press). DOI: 10.4269/ajtmh.22-0749
Nsanzabana C. Time to scale up molecular surveillance for anti-malarial drug resistance in sub-Saharan Africa. Malar J. 2021;20:401. DOI: 10.1186/s12936-021-03942-5
Nsanzabana C. Strengthening surveillance systems for malaria elimination by integrating molecular and genomic data. Trop Med Infect Dis. 2019;4:139. DOI: 10.3390/tropicalmed4040139
Nsanzabana C. Resistance to Artemisinin Combination Therapies (ACTs): do not forget the partner drug!. Trop Med Infect Dis. 2019;4(1):26. DOI: 10.3390/tropicalmed4010026
WorldWide Antimalarial Resistance Network (WWARN) - AS-AQ Study Group. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:66. DOI: 10.1186/s12916-015-0301-z
WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212. DOI: 10.1186/s12916-015-0445-x